Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics, Inc. announced positive interim data from its Phase 2b ORIGIN clinical trial of atacicept in IgA Nephropathy (IgAN), revealing a 41% mean reduction in proteinuria for the 150mg dose group at 24 weeks. The company plans to start a Phase 3 clinical trial in Q2 2023 and expects to release 36-week data from ORIGIN then. Vera reported a net loss of $89.1 million for 2022, increasing from $32.6 million in the previous year. Despite this, it has a strong balance sheet with approximately $188 million from recent follow-on offerings, supporting operations through early 2026.
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston from March 6 – 8, 2023. The chat is scheduled for March 6 at 2:10 PM ET and will be available via webcast. Additionally, the management team will hold one-on-one investor meetings at the event. Vera focuses on developing transformative treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting conditions like IgA nephropathy and lupus nephritis. A replay of the event will be accessible for 90 days on their website.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
